complement factor H related 4Genealiases: CFHL4 · FHR-4 · FHR4
Q-omics provides the consensus-scored CFHR4 profile across patient tissues and cancer cell-line models. CFHR4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CFHR4 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, CFHR4 protein abundance shows 29,202 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, and PDAC as cancer lineages where CFHR4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CFHR4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CFHR4 survival associations across molecular data types. CFHR4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CFHR4 RNA expression–survival associations across cancer types. High CFHR4 expression shows unfavorable associations in KIRC, CHOL, PAAD, TGCT and KICH, but favorable associations in LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CFHR4 RNA expression.
This table summarizes CFHR4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CFHR4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CFHR4 shows lower tumor expression in KIRC, LIHC, KICH, KIRP and CHOL and higher tumor expression in LUAD. The KIRC box plot shows higher CFHR4 RNA expression in normal versus tumor tissue (log2 FC = −0.156, t-test p < 0.001).
This table shows molecular features associated with CFHR4 in patient tissues and cancer cell lines. In patient samples, CFHR4 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, CFHR4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
